Sign In
Buy PHIO
$1.03
-0.0050 (-0.485%)
At Close: Jul 31, 2026
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
05:00pm, Thursday, 23'rd May 2024
Phio to present a clinical study progress update on their lead clinical candidate, PH-762 Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a cli
Phio Pharmaceuticals Secures New Investor
09:00am, Friday, 17'th May 2024
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is d
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
01:00pm, Wednesday, 15'th May 2024
- PH-762 is Phio's lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage bio
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
05:25pm, Thursday, 09'th May 2024
–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 – Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- P
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
07:30am, Tuesday, 30'th Apr 2024
-Phio's lead clinical product candidate, PH-762, is the focus of dermatological poster presentation -Phio's lead clinical product candidate, PH-762, is the focus of dermatological poster presentation
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MA
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
07:30am, Tuesday, 16'th Apr 2024
Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
07:30am, Thursday, 11'th Apr 2024
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is
National Spotlight Features Phio's Innovative RNAi Technology Platform
07:30am, Wednesday, 03'rd Apr 2024
—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: P
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
07:30am, Tuesday, 02'nd Apr 2024
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatmen
MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is
Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
08:00am, Wednesday, 31'st Jan 2024
--New preclinical data to be presented at Immunotherapy Conference in Germany MARLBOROUGH, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechn
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
08:00am, Thursday, 07'th Dec 2023
MARLBOROUGH, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designe
Penny Stocks To Buy Now? 5 Under $5 To Watch This Week
05:10pm, Tuesday, 05'th Dec 2023
Penny stocks, defined as those trading under $5 per share, offer unique opportunities. With low prices and the potential for high percentage returns, it's understandable why penny stocks attract inter
